BioSpace News Archive

The Parkinson’s Foundation today announced the preliminary results from the PD GENEration: Mapping the Future of Parkinson’s Disease pilot study. PD GENEration is a first-of-its kind national initiative that offers fr

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced submission of a publication providing preclinical data which supports repositioning of its Cancer Immunotherapy StemVacs™ as a candidate

Vxtra Health, a new entry in the burgeoning health insurtech market announced today the appointment of Tim Attebery as chairman of the board. Recognized as one of the most innovative healthcare executives in America, Attebery joins the

Avoid fluoride during pregnancy and infancy to protect babies’ brains, caution fluoride researchers in the Journal of Pediatrics (“Current Best Evidence,” July 2020), reports the New York State Coalition Opposed to Fluoridation, Inc. (NYSCOF).

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib,

Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF Key milestone and validation for Evive’s novel biologic development capability and technology platform Key component of the asset’s BLA submission to receive regulatory approval from the FDA Completes robust development program involving 10 succe

Sorrel Medical (sorrelmedical.com), a developer and manufacturer of wearable drug delivery devices, today announced the opening of a new manufacturing facility with state-of-the-art cleanroom facilities to accommodate manufacturing scalability of its wearable drug delivery devices.

The data has been submitted to the EPA for review to include claims of disinfection against the virus on the label

Studies show Signatera’s accuracy in identifying 100% of stage IV oligometastatic CRC patients in a pre-surgical setting, and the clinical utility of Signatera in optimizing post-surgical treatment decisions for patients with Stage II-III CRC and stage IV oligometastatic CRC [07-July-2020] SAN CARLOS, Calif. , July 7, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTR

EHO360 is an experienced national Hospice Pharmacy Benefit Manager with a deep understanding of the hospice system with hospice provider clients across the country.